BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,074,144 | -17.9% | 15,780 | -1.6% | 0.01% | -10.0% |
| Q2 2023 | $1,308,447 | -6.5% | 16,029 | -15.0% | 0.01% | -16.7% |
| Q1 2023 | $1,399,223 | -66.4% | 18,860 | -62.4% | 0.01% | -67.6% |
| Q4 2022 | $4,161,322 | -6.7% | 50,209 | +219.6% | 0.04% | -9.8% |
| Q3 2022 | $4,461,000 | -27.2% | 15,708 | -11.1% | 0.04% | -14.6% |
| Q2 2022 | $6,126,000 | -24.4% | 17,673 | -5.6% | 0.05% | -2.0% |
| Q1 2022 | $8,107,000 | -24.9% | 18,720 | -10.2% | 0.05% | -12.5% |
| Q4 2021 | $10,788,000 | +42.9% | 20,855 | +33.8% | 0.06% | +24.4% |
| Q3 2021 | $7,551,000 | +5.9% | 15,582 | -1.6% | 0.04% | +7.1% |
| Q2 2021 | $7,132,000 | +14.9% | 15,841 | -2.5% | 0.04% | +2.4% |
| Q1 2021 | $6,208,000 | +12.7% | 16,254 | -6.3% | 0.04% | +17.1% |
| Q4 2020 | $5,507,000 | +6.2% | 17,344 | -17.1% | 0.04% | -7.9% |
| Q3 2020 | $5,185,000 | -17.4% | 20,932 | -11.9% | 0.04% | -22.4% |
| Q2 2020 | $6,277,000 | +55.5% | 23,770 | +11.7% | 0.05% | +19.5% |
| Q1 2020 | $4,036,000 | -26.8% | 21,283 | -15.3% | 0.04% | 0.0% |
| Q4 2019 | $5,515,000 | +43.6% | 25,123 | +28.0% | 0.04% | +32.3% |
| Q3 2019 | $3,841,000 | -41.3% | 19,629 | -37.5% | 0.03% | -41.5% |
| Q2 2019 | $6,547,000 | +33.2% | 31,402 | +26.9% | 0.05% | +32.5% |
| Q1 2019 | $4,914,000 | +31.3% | 24,747 | -4.3% | 0.04% | +25.0% |
| Q4 2018 | $3,742,000 | -42.3% | 25,857 | -18.6% | 0.03% | -23.8% |
| Q3 2018 | $6,484,000 | +20.9% | 31,767 | -12.3% | 0.04% | +16.7% |
| Q2 2018 | $5,362,000 | -52.2% | 36,241 | -51.2% | 0.04% | +33.3% |
| Q1 2018 | $11,229,000 | +10.8% | 74,340 | -5.0% | 0.03% | +12.5% |
| Q4 2017 | $10,139,000 | -19.7% | 78,261 | -25.1% | 0.02% | -20.0% |
| Q3 2017 | $12,627,000 | +13.1% | 104,432 | +9.9% | 0.03% | 0.0% |
| Q2 2017 | $11,168,000 | +14.2% | 95,037 | -1.2% | 0.03% | +11.1% |
| Q1 2017 | $9,781,000 | -3.5% | 96,226 | -2.4% | 0.03% | -6.9% |
| Q4 2016 | $10,137,000 | +23.5% | 98,581 | +31.5% | 0.03% | +11.5% |
| Q3 2016 | $8,210,000 | -9.6% | 74,973 | -6.9% | 0.03% | -10.3% |
| Q2 2016 | $9,085,000 | +2.5% | 80,567 | -14.1% | 0.03% | +3.6% |
| Q1 2016 | $8,865,000 | -19.8% | 93,794 | -23.6% | 0.03% | -12.5% |
| Q4 2015 | $11,055,000 | +23.2% | 122,841 | +26.6% | 0.03% | +14.3% |
| Q3 2015 | $8,975,000 | -7.2% | 97,069 | -1.1% | 0.03% | +16.7% |
| Q2 2015 | $9,669,000 | +10.6% | 98,190 | +12.6% | 0.02% | +14.3% |
| Q1 2015 | $8,745,000 | +39.9% | 87,195 | +28.9% | 0.02% | +31.2% |
| Q4 2014 | $6,253,000 | – | 67,671 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |